Astellas Pharma Inc.
4503.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥2,589,531,533 | ¥2,942,765,916 | ¥3,427,095,777 | ¥3,534,801,543 |
| - Cash | ¥188,372,000 | ¥335,687,000 | ¥376,840,000 | ¥315,986,000 |
| + Debt | ¥831,426,000 | ¥1,005,716,000 | ¥200,007,000 | ¥212,744,000 |
| Enterprise Value | ¥3,232,585,533 | ¥3,612,794,916 | ¥3,250,262,777 | ¥3,431,559,543 |
| Revenue | ¥1,912,323,000 | ¥1,603,672,000 | ¥1,518,619,000 | ¥1,296,163,000 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | ¥1,426,355,000 | ¥1,311,187,000 | ¥1,230,266,000 | ¥1,043,154,000 |
| % Margin | 74.6% | 81.8% | 81% | 80.5% |
| EBITDA | ¥248,303,000 | ¥195,340,000 | ¥240,459,000 | ¥241,030,000 |
| % Margin | 13% | 12.2% | 15.8% | 18.6% |
| Net Income | ¥50,747,000 | ¥17,045,000 | ¥98,714,000 | ¥124,086,000 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | ¥201,613,000 | ¥172,475,000 | ¥327,767,000 | ¥257,444,000 |
| Capital Expenditures | -¥37,003,000 | -¥82,497,000 | -¥88,541,000 | -¥76,448,000 |
| Free Cash Flow | ¥164,610,000 | ¥89,978,000 | ¥239,226,000 | ¥180,996,000 |